CLOUDBREAK-B (02592) rose over 10% again, bringing its cumulative weekly gain to nearly 70%. At the time of writing, the stock was up 8.82% to HK$7.9, with a turnover of HK$6.22 million.

The company announced that its wholly-owned U.S. subsidiary, ADS USA, has secured patents from the Japan Patent Office and the European Patent Office for its core product CBT-009. This development is expected to facilitate partnerships with major pharmaceutical firms for the production, development, and distribution of CBT-009 in Japan and Europe under licensing agreements.

CBT-009 is a novel atropine-based ophthalmic formulation designed to treat myopia in children and adolescents aged 5 to 19.

Notably, on January 3, 2026, two cornerstone investors of CLOUDBREAK-B will see their lock-up shares lifted. Earlier market performance suggests that the stock's rally may not be driven by underwriter-led stabilization efforts but rather by insufficient institutional participation in the placement. The subdued trading during the gray market and on its debut could be attributed to anchor investors holding larger-than-expected positions, triggering a sell-off.